Sichuan Kelun-Biotech Biopharmaceutical news

Latest news

• 
  Multiple Sacituzumab Tirumotecan (sac-TMT) Studies Selected as LBAs at ESMO 2026, OptiTROP-Lung04 and OptiTROP-Lung06 to be Presented in the Lung Cancer Session (opens in a new tab)

  Sep 22, 2026

• 
  Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO (opens in a new tab)

  Sep 14, 2026

• 
  Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study (opens in a new tab)

  Sep 8, 2026

• Why Merck Stock Got Downgraded After a Massive Cancer-Vaccine Win (opens in a new tab)

  Aug 20, 2026

• Kelun-Biotech Announces 2026 Interim Results (opens in a new tab)

  Aug 17, 2026

• Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Following New TNBC Filing Has Valuation Back In Focus (opens in a new tab)

  Aug 2, 2026

• Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Stock May Trade At A Premium Despite Priority Review News (opens in a new tab)

  Aug 2, 2026

• NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC (opens in a new tab)

  Jul 30, 2026

• Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565 (opens in a new tab)

  Jul 27, 2026

• Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy (opens in a new tab)

  Jul 16, 2026

• Can Dow Jones' Merck Nab $25 Billion With Its Smart Bomb For Cancer? (opens in a new tab)

  Jul 15, 2026

• Merck ADC, in China study, shows potential to replace chemo in lung cancer (opens in a new tab)

  Jul 15, 2026

• Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthma (opens in a new tab)

  Jul 15, 2026

• Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthma (opens in a new tab)

  Jul 15, 2026